

In the Claims

1-94 (canceled).

95. (currently amended) An isolated polypeptide consisting of:

- a) SEQ ID NO: 6;
- b) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R);
- c) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said polypeptide contains SEQ ID NO: 13 and binds to OX40R;
- d) SEQ ID NO: 8 or SEQ ID NO: 13;
- e) an active mutant of a), b), c) or d), wherein one or more of the amino acids has been conservatively substituted and said active mutant binds to OX40R;
- f) a fusion polypeptide or peptide comprising a first amino acid sequence and a second amino acid sequence, wherein said first amino acid sequence is a protein sequence other than human OX40L fused to a second amino acid sequence selected from:
 - i) SEQ ID NO: 6;
 - ii) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said second amino acid sequence polypeptide contains SEQ ID NO: 13 and said fusion polypeptide binds to the OX40 receptor (OX40R);
 - iii) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said ~~polypeptide contains contiguous amino acids of SEQ ID NO: 1~~ contain SEQ ID NO: 13 and said fusion polypeptide binds to OX40R;or
 - iv) SEQ ID NO: 8 or SEQ ID NO: 13; or
- g) a conjugate or derivative of a), b), c), d), e) or f).

96. (previously presented) The isolated polypeptide according to claim 95, wherein said fusion polypeptide or peptide comprises the amino acid sequence belonging to one or more of the following protein sequences: membrane-bound proteins, extracellular domains of membrane-bound protein, immunoglobulin constant region, multimerization domains, extracellular proteins, signal peptide-containing proteins, export signal-containing proteins.

97. (currently amended) The isolated polypeptide according to claim 95, ~~wherein further comprising a molecule selected from the group consisting of radioactive labels, biotin, fluorescent labels, cytotoxic agents, and drug delivery agents~~ is conjugated to a polypeptide according to claim 95a), b), c), d), e) or f).

98. (previously presented) The isolated polypeptide according to claim 95, wherein said polypeptide consists of SEQ ID NO: 6.

99. (previously presented) The isolated polypeptide according to claim 95, wherein said polypeptide consists of SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R).

100. (currently amended) The isolated polypeptide according to claim 95, wherein said polypeptide consists of between 5 and 10 contiguous amino acids of ~~between 5 and 10 contiguous amino acids of~~ SEQ ID NO: 1, ~~wherein said polypeptide contains~~ SEQ ID NO: 13 and binds to OX40R.

101. (previously presented) The isolated polypeptide according to claim 95, wherein said polypeptide consists of SEQ ID NO: 8.

102. (previously presented) The isolated polypeptide according to claim 95, wherein said polypeptide consists of SEQ ID NO: 13.

103. (previously presented) The isolated polypeptide according to claim 95, wherein said polypeptide consists of an active mutant of a), b), c) or d), wherein three or fewer amino acids are conservatively substituted and said active mutant binds to OX40R.

104. (currently amended) The isolated polypeptide according to claim 95, wherein said polypeptide is a fusion polypeptide or peptide ~~comprising a protein sequence other than human OX40L fused to~~ and said second amino acid sequence is a peptide consisting of ~~amino acids 94-124 of human OX40L~~ SEQ ID NO: 6.

105. (canceled).

106. (currently amended) The isolated polypeptide according to claim 95, wherein said polypeptide is a fusion polypeptide or peptide ~~and said second amino acid sequence is comprising a protein sequence other than human OX40L fused to~~ SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said fusion polypeptide or peptide ~~polypeptide~~ binds to the OX40 receptor (OX40R).

107. (currently amended) The isolated polypeptide according to claim 95, wherein said polypeptide is a fusion polypeptide or peptide ~~comprising a protein sequence other than human OX40L fused to a~~ and said second amino acid sequence is a peptide consisting of between 5 and 10 contiguous amino acids of SEQ ID NO: 1 that contains, wherein said polypeptide contains SEQ ID NO: 13 and said fusion polypeptide or peptide binds to OX40R.

108. (currently amended) The isolated polypeptide according to claim 95, wherein said polypeptide is a fusion polypeptide or peptide ~~and said second amino acid sequence is comprising a protein sequence other than human OX40L fused to~~ a peptide consisting of SEQ ID NO: 8 or SEQ ID NO: 13.

109. (previously presented) The isolated polypeptide according to claim 95, wherein said polypeptide is a derivative of a), b), c), d), e) or f).

110. (previously presented) The isolated polypeptide according to claim 95, wherein said polypeptide antagonizes the activity of OX40R.

111. (currently amended) A composition comprising a pharmaceutically acceptable carrier, excipient, stabilizer, diluent, or combination thereof and a polypeptide consisting of:

- a) — SEQ ID NO: 6;
- b) — SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R);
- c) — between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said polypeptide contains SEQ ID NO: 13 and binds to OX40R;
- d) — SEQ ID NO: 8 or SEQ ID NO: 13;
- e) — an active mutant of a), b), c) or d), wherein one or more of the amino acids has been conservatively substituted and said active mutant binds to OX40R;
- f) — a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to:
 - i) — SEQ ID NO: 6;
 - ii) — SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R);
 - iii) — between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said polypeptide contains SEQ ID NO: 13 and binds to OX40R; or
 - iv) — SEQ ID NO: 8 or SEQ ID NO: 13; or
- g) — a derivative of a), b), c), d), e) or f)
- a) — SEQ ID NO: 6;

- b) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R);
- c) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said polypeptide contains SEQ ID NO: 13 and binds to OX40R;
- d) SEQ ID NO: 8 or SEQ ID NO: 13;
- e) an active mutant of a), b), c) or d), wherein one or more of the amino acids has been conservatively substituted and said active mutant binds to OX40R;
- f) a fusion polypeptide or peptide comprising a first amino acid sequence and a second amino acid sequence, wherein said first amino acid sequence is a protein sequence other than human OX40L fused to a second amino acid sequence selected from:
 - i) SEQ ID NO: 6;
 - ii) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said second amino acid sequence contains SEQ ID NO: 13 and said fusion polypeptide binds to the OX40 receptor (OX40R);
 - iii) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said contiguous amino acids of SEQ ID NO: 1 contain SEQ ID NO: 13 and said fusion polypeptide binds to OX40R; or
 - iv) SEQ ID NO: 8 or SEQ ID NO: 13; or
- g) a conjugate or derivative of a), b), c), d), e) or f).

112. (previously presented) The composition according to claim 111, wherein said polypeptide consists of SEQ ID NO: 6.

113. (previously presented) The composition according to claim 111, wherein said polypeptide consists of SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R).

114. (currently amended) The composition according to claim 111, wherein said polypeptide consists of between 5 and 10 contiguous amino acids of ~~between 5 and 10 contiguous amino acids of~~ SEQ ID NO: 1, ~~wherein said polypeptide contains~~ SEQ ID NO: 13 and binds to OX40R.

115. (previously presented) The composition according to claim 111, wherein said polypeptide consists of SEQ ID NO: 8.

116. (previously presented) The composition according to claim 111, wherein said polypeptide consists of SEQ ID NO: 13.

117. (previously presented) The composition according to claim 111, wherein said polypeptide consists of an active mutant of a), b), c) or d), wherein three or fewer amino acids are conservatively substituted and said active mutant binds to OX40R and said polypeptide contains SEQ ID NO: 13.

118. (currently amended) The composition according to claim 111, wherein said polypeptide is a fusion polypeptide or peptide and said second amino acid sequence comprising a protein sequence other than human OX40L fused to a peptide consisting- consists of SEQ ID NO: 13.

119. (currently amended) The composition according to claim 111, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting- and said second amino acid sequence consists of SEQ ID NO: 6.

120. (currently amended) The composition according to claim 111, wherein said polypeptide is a fusion polypeptide or peptide and said second amino acid sequence comprising a protein sequence other than human OX40L fused to is SEQ ID NO: 6, wherein one or more amino acids have been deleted, said second amino acid sequence ~~polypeptide~~ contains SEQ ID NO: 13 and said fusion polypeptide or peptide ~~polypeptide~~ binds to the OX40 receptor (OX40R).

121. (currently amended) The composition according to claim 111, wherein said polypeptide is a fusion polypeptide or peptide and said second amino acid sequence comprising a protein sequence other than human OX40L fused to a peptide consisting ~~consists~~ of between 5 and 10 contiguous amino acids of SEQ ID NO: 1, ~~wherein said polypeptide contains~~ SEQ ID NO: 13 and said fusion polypeptide or peptide binds to OX40R.

122. (currently amended) The composition according to claim 111, wherein said polypeptide is a fusion polypeptide or peptide and said second amino acid sequence consists ~~comprising a protein sequence other than human OX40L fused to a peptide consisting~~ of SEQ ID NO: 8 or SEQ ID NO: 13.

123. (previously presented) The composition according to claim 111, wherein said polypeptide is a derivative of a), b), c), d), e) or f).

124. (currently amended) A composition of matter comprising a solid support and a polypeptide consisting of:

- a) SEQ ID NO: 6;
- b) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R);
- c) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said polypeptide contains SEQ ID NO: 13 and binds to OX40R;
- d) SEQ ID NO: 8 or SEQ ID NO: 13;
- e) an active mutant of a), b), c) or d), wherein one or more of the amino acids has been conservatively substituted and said active mutant binds to OX40R;
- f) a fusion polypeptide or peptide comprising a first amino acid sequence and a second amino acid sequence, wherein said first amino acid sequence is a protein sequence other than human OX40L fused to a second amino acid sequence selected from:

- i) SEQ ID NO: 6;
- ii) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said second amino acid sequence contains SEQ ID NO: 13 and said fusion polypeptide binds to the OX40 receptor (OX40R);
- iii) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said contiguous amino acids of SEQ ID NO: 1 contain SEQ ID NO: 13 and said fusion polypeptide binds to OX40R; or
- iv) SEQ ID NO: 8 or SEQ ID NO: 13; or
- g) a conjugate or derivative of a), b), c), d), e) or f)
- a) SEQ ID NO: 6;
- b) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R);
- c) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said polypeptide contains SEQ ID NO: 13 and binds to OX40R;
- d) SEQ ID NO: 8 or SEQ ID NO: 13;
- e) an active mutant of a), b), c) or d), wherein one or more of the amino acids has been conservatively substituted and said active mutant binds to OX40R;
- f) a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to:
 - i) SEQ ID NO: 6;
 - ii) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R);
 - iii) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said polypeptide contains SEQ ID NO: 13 and binds to OX40R; or
 - iv) SEQ ID NO: 8 or SEQ ID NO: 13; or
- g) a derivative of a), b), c), d), e) or f).

125. (previously presented) The composition of matter according to claim 124, wherein said polypeptide consists of SEQ ID NO: 6.

126. (previously presented) The composition of matter according to claim 124, wherein said polypeptide consists of SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R).

127. (currently amended) The composition of matter according to claim 124, wherein said polypeptide consists of between 5 and 10 contiguous amino acids of ~~between 5 and 10 contiguous amino acids of~~ SEQ ID NO: 1, ~~wherein said polypeptide contains~~ SEQ ID NO: 13 and binds to OX40R.

128. (previously presented) The composition of matter according to claim 124, wherein said polypeptide consists of SEQ ID NO: 8.

129. (previously presented) The composition of matter according to claim 124, wherein said polypeptide consists of SEQ ID NO: 13.

130. (previously presented) The composition of matter according to claim 124, wherein said polypeptide consists of an active mutant of a), b), c) or d), wherein three or fewer amino acids are conservatively substituted and said active mutant binds to OX40R and said polypeptide contains SEQ ID NO: 13.

131. (currently amended) The composition of matter according to claim 124, wherein said polypeptide is a fusion polypeptide or peptide and said second amino acid sequence consists comprising a protein sequence other than human OX40L fused to a peptide consisting of SEQ ID NO: 6.

132. (canceled)

133. (currently amended) The composition of matter according to claim 124, wherein said polypeptide is a fusion polypeptide or peptide and said second amino acid sequence is comprising a protein sequence other than human OX40L fused to SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide second amino acid sequence contains SEQ ID NO: 13 and said fusion polypeptide or peptide binds to the OX40 receptor (OX40R).

134. (currently amended) The composition of matter according to claim 124, wherein said polypeptide is a fusion polypeptide or peptide and said second amino acid sequence comprising a protein sequence other than human OX40L fused to a peptide consisting consists of between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said polypeptide contains SEQ ID NO: 13 and said fusion polypeptide or peptide binds to OX40R.

135. (currently amended) The composition of matter according to claim 124, wherein said polypeptide is a fusion polypeptide or peptide and said second amino acid sequence consists comprising a protein sequence other than human OX40L fused to a peptide consisting of SEQ ID NO: 8 or SEQ ID NO: 13.

136. (previously presented) The composition of matter according to claim 124, wherein said polypeptide is a derivative of a), b), c), d), e) or f).

137. (previously presented) An isolated peptide, peptide mimetic, or a non-peptide mimetic of SEQ ID NO: 8 or SEQ ID NO: 13.

138. (previously presented). The isolated polypeptide according to claim 95, wherein said polypeptide is acetylated, carboxylated or PEGylated.